Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The U.K.'s NICE issued a preliminary appraisal recommending the use of Pegasys peginterferon alfa-2a from Roche (SIX:ROG; OTCQX:RHHBY,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury